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Abstract
Background: Worldwide, traumatic brain injury (TBI) kills or hospitalises over
10 million people each year. Early intracranial bleeding is common after TBI,
increasing the risk of death and disability. Tranexamic acid reduces blood loss
in surgery and death due to bleeding in trauma patients with extra-cranial injury.
Early administration of tranexamic acid in TBI patients might limit intracranial
bleeding, reducing death and disability. The CRASH-3 trial aims to provide
evidence on the effect of tranexamic acid on death and disability in TBI
patients. We will randomly allocate about 13,000 TBI patients (approximately
10,000 within 3 hours of injury) to an intravenous infusion of tranexamic acid or
matching placebo in addition to usual care. This paper presents a protocol
update (version 2.1) and statistical analysis plan for the CRASH-3 trial.
Results: The primary outcome is head injury death in hospital within 28 days of
injury for patients treated within 3 hours of injury (deaths in patients treated after
3 hours will also be reported). Because there are reasons to expect that
tranexamic acid will be most effective in patients treated immediately after
injury and less effective with increasing delay, the effect in patients treated
within one hour of injury is of particular interest. Secondary outcomes are
all-cause and cause-specific mortality, vascular occlusive events, disability
based on the Disability Rating Scale and measures suggested by patient
representatives, seizures, neurosurgical intervention, neurosurgical blood loss,
days in intensive care and adverse events. Sub-group analyses will examine
the effect of tranexamic acid on head injury death stratified by time to treatment,
severity of TBI and baseline risk.
Conclusion: The CRASH-3 trial will provide reliable evidence of the
effectiveness and safety of tranexamic acid in patients with acute TBI.
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REVISED

Amendments from Version 1

The revised version has been updated in the light of the reviewers
comments:
Specifically we have:
1. Explained in the abstract that we hope to have up to 10,000
patients within 3 hours of injury.
2. Explained that the original sample size estimate was 10,000
patients overall but that now we aim to have this many patients
within 3 hours of injury.
3. Explained that means and SD will be presented for continuous
baseline variables.
4. Explained that the primary analyses will present relative risks.
5. Acknowledged that time to treatment is estimated.
6. Explained where the data for the Figure came from.
7. Removed the sentence: "However, we hypothesise that the risk
reduction with tranexamic acid would be greatest in patients at
low risk of death since a smaller proportion of these patients will
have un-survivable TBI." This was an error left over from an earlier
version.
8. Laid out abbreviations and corrected minor typos.
See referee reports

List of abbreviations
AEs: Adverse events; CI: Confidence interval; CONSORT:
Consolidated Standards of Reporting Trials; CRASH-2: Clinical
randomisation of an anti-fibrinolytic in significant haemorrhage;
CRASH-3: Clinical randomisation of an anti-fibrinolytic in
significant head injury; CT: Computed tomography; DMP: Data
Management Plan; DIC: Disseminated intravascular coagulation;
GCS: Glasgow coma scale; HIV: Human immunodeficiency
virus; ICH-GCP: International Conference on Harmonization – Good Clinical Practice; IBMS: Intracranial Bleeding
Mechanistic Sub-study; ICU: Intensive Care Unit; LSHTM:
London School of Hygiene and Tropical Medicine; PAI-1:
Plasminogen activator inhibitor-1; RR: Relative risk; SAEs:
Serious adverse events; SUSARs: Suspected unexpected
serious adverse reaction; TB: Tuberculosis; TBI: Traumatic brain
injury; TPA: Tissue plasminogen activator; TXA: Tranexamic
acid; UK: United Kingdom; USA: United States of America

Introduction
There are more deaths each year from injuries than from
HIV, TB and malaria combined1. Worldwide, over ten million
people are killed or hospitalised each year after traumatic brain
injury (TBI)2. Road traffic crashes are the main cause of serious TBI. Most of the deaths are in low and middle income countries where the TBI incidence is high due to rapidly increasing
motorisation3. Africa and South Asia have particularly high
TBI rates, due to their high rate of traffic crashes3.
Early intracranial bleeding is common after TBI and increases
the risk of death and disability4. In patients with moderate and
severe TBI, intracranial bleeding may continue after hospital
admission and for several hours after injury5–7. Abnormal
coagulation with increased fibrinolysis may worsen intracranial
bleeding8. High levels of fibrin degradation products are often

seen in the first three hours9. These patients have a higher risk
of intracranial bleeding and death.
Tranexamic acid reduces bleeding by inhibiting the enzymatic
breakdown of fibrinogen and fibrin. A systematic review of
randomized trials of tranexamic acid in surgery showed that
tranexamic acid reduces blood loss by one third10. Tranexamic acid also reduces mortality in bleeding trauma patients.
In 2011, the CRASH-2 trial showed that administration of
tranexamic acid to poly-trauma patients within three hours
of injury reduces deaths due to bleeding by about one third11,12.
In 2017, the WOMAN trial showed that administration of tranexamic acid to women with post-partum haemorrhage within
three hours of delivery reduces deaths due to bleeding by about
one third13. Later in 2017, results from an individual patient-level
data meta-analysis of randomised trials of tranexamic acid in
acute severe bleeding showed that whilst immediate treatment
substantially improves survival, the survival benefit decreases by
around 10% for every 15 min of treatment delay until 3 h, after
which there was no benefit14.
The CRASH-3 trial is an international, randomized, placebocontrolled trial to quantify the effects of early administration of tranexamic acid on death and disability in patients with
TBI. We expect tranexamic acid to be more effective than
placebo in reducing death and disability in patients with TBI.
We published the protocol before the start of the trial15. In
September 2016 we increased the sample size from 10,000 to
13,000 patients. In this paper, we provide the reason for this
increase. This statistical analysis plan was completed and submitted
for publication before the treatment allocation was un-blinded.

Trial methods
Trial design and patients
The CRASH-3 trial is an international, multi-centre, randomised,
parallel group, double blind, placebo controlled trial of the effects
of early administration (within 3 hours of injury) of tranexamic
acid on death and disability in TBI patients. Adults with TBI
within 3 hours of injury, with any intracranial bleeding on CT
scan or who have a GCS of 12 or less, and no significant extra
cranial bleeding are potentially eligible. The time window for
eligibility was originally within 8 hours of injury but in 2016
the protocol was amended to limit recruitment to patients who
are within 3 hours of injury. We will randomly allocate approximately 13,000 TBI patients who meet the eligibility criteria
to receive tranexamic acid or placebo. The primary outcome
is head injury death in hospital within 28 days of injury in
patients treated within 3 hours of injury.

Trial registration
The CRASH-3 trial was prospectively registered at the International Standard Randomised Controlled Trials registry
(ISRCTN15088122) on 19 July 2011, and ClinicalTrials.gov on
25 July 2011 (NCT01402882).
Ethics approval
The Medical Research and Ethics Committee and Health
Research Authority reviewed the protocol and supporting
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documents for the CRASH-3 trial and provided a favourable
ethical opinion on 19 July 2012 (Research Ethics Committee
Reference 12/EE/0274). The Medicines and Healthcare Products
Regulatory Agency authorised the CRASH-3 trial on 8 August
2012 (Reference 17072/0007/001-0001). Favourable ethical opinion was received from the Observational/Interventions Research
Ethics Committee at the London School of Hygiene and Tropical
Medicine (LSHTM) on 17 November 2011 (Reference 6060). The
Medical Research and Ethics Committee and Health Research
Authority reviewed the protocol and supporting documents for the
IBMS and provided a favourable ethical opinion on 8 June 2016
(Research Ethics Committee Reference 12/EE/0274). Favourable
ethical opinion was received from the Observational/Interventions
Research Ethics Committee at the London School of
Hygiene and Tropical Medicine on 24 May 2016 (Reference
11535). Important protocol modifications to the CRASH-3
trial will be submitted to and reviewed by the Medicines and
Healthcare Products Regulatory Agency, Medical Research and
Ethics Committee and Health Research Authority, and registries
updated as appropriate. All ethical approvals have been reviewed
in support of publication of the CRASH-3 trial protocols15,16.

Baseline information will be collected on the entry form and
the next lowest consecutively numbered pack will be taken
from a box of eight treatment packs. If the treatment ampoule is
confirmed as intact, the patient is considered randomised. Entry
form data should be sent to the Trial Coordinating Centre as
soon as possible. Both participants and study staff (site investigators and trial coordinating centre staff) will be masked to
allocation. An emergency un-blinding service is available. The
tranexamic acid (Cyklokapron® Injection) used in the trial
is manufactured by Pfizer Ltd Sandwich (UK). The South
Devon Healthcare NHS Trust (UK) manufacture the matching
placebo (sodium chloride, 0.9%). Ampoules and packaging
are identical in appearance. The blinding is done by Brecon
Pharmaceuticals Limited (Hereford, UK). The blinding process
involves removal of the original manufacturer’s label and
replacement with the clinical trial label bearing the randomisation number (the pack identification). All pack label texts
are identical for both tranexamic and placebo. We check
the coding of blinded ampoules by randomly testing each
batch of trial treatments and doing high performance liquid
chromatography to check the contents.

Consent to participate
TBI patients are physically and mentally incapable of providing
informed consent to participate in a clinical trial. As acknowledged in the Declaration of Helsinki, patients who are incapable
of giving consent are an exception to the general rule of informed
consent in clinical trials (34). In the CRASH-3 trial, patients
are unable to provide consent and so consent is sought from
the patient’s relative, legal representative or the responsible
clinician. If and when the patient regains capacity to provide
informed consent, they are informed about the trial and written
consent sought to continue their participation in the trial. If
a patient or patient representative declines consent, they are
withdrawn from the trial. For patients who were included in
the trial but did not regain capacity, written informed consent is
sought from a relative or legal representative. The requirements
of relevant local and national ethics committees are adhered
to at all times. The CRASH-3 trial includes consent to extract
data from patient medical records. Collecting CT scan data for
the IBMS is consistent with the consent procedure used in the
CRASH-3 trial. It would be impractical to re-consent patients or
relatives/legal representatives to access CT scans, particularly
for patients who have deceased or are disabled as a result of
their injuries where re-consent would be distressing and unwelcome. LSHTM and national Ethics Committees extended their
approvals to extract CT data from the CRASH-3 trial without
further patient consent. Patients who withdrew from the main
CRASH-3 trial would not be included in the IBMS.

Trial procedures
When eligibility has been confirmed and the consent procedure
followed, each patient is assigned a uniquely numbered treatment
pack and are thus randomly allocated to receive tranexamic acid
(loading dose 1g over 10 minutes followed by an infusion of 1g
over 8 hours) or matching placebo. Once randomised, we will
collect patient outcome data even if the trial treatment is not
given. Outcome data are collected four weeks (28 days) after
randomisation, at discharge from the randomising hospital or at
death (whichever occurs first).

Randomisation and masking
An independent statistical consultant from Sealed Envelope
Ltd (UK) prepared and secured the randomisation codes.
They were then given to the drug packers so that treatment
packs could be prepared in accordance with the randomisation
list. We will randomise TBI patients eligible for inclusion to
receive active treatment (tranexamic acid) or placebo (sodium
chloride, 0.9%) intravenously. Half of the patients will receive
tranexamic acid whilst the other half will receive placebo.

Sample size
We originally estimated that a trial with about 10,000 patients
would have 90% power (two-sided alpha of 1%) to detect a
15% relative reduction (20% to 17%) in mortality. However,
whilst the trial was underway, new research suggested a shorter
therapeutic window than 8 hours12,13. The new data showed that
tranexamic acid is most likely to improve outcome if given soon
after injury and would be unlikely to improve outcome if given
beyond three hours of injury. In response to this evidence, in
September 2016, we changed the primary outcome to head
injury death in hospital within 28 days of injury in patients
randomised within 3 hours of injury. We also limited recruitment
to within 3 hours. We increased the sample size to 13,000 to
get enough patients (about 10,000 as per the original sample
size calculation) within 3 hours of injury to confirm or refute
an early benefit. Statisticians at the London School of Hygiene
and Tropical Medicine (University of London) have reviewed
the sample size calculations.

Statistical analysis plan
Trial profile
We will show the flow of study participants in a Consolidated
Standards of Reporting Trials (CONSORT) diagram. This will
include the total number of participants randomised into the
trial divided by treatment arm. Each treatment arm will detail
the number of patients who withdrew consent, the number of
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patients for whom baseline data was collected, the number lost
to follow up and the number of patients for whom outcome data
was collected. Because TBI is a life-threatening emergency,
we do not ask clinicians to complete a screening log since this
would take time away from important clinical work. We will
report the number of patients included in the primary and secondary analyses, the reasons for any post-randomisation exclusions
and the number lost to follow-up. We will count patients that did
not fulfil the eligibility criteria or did not receive their allocated
treatment as having deviated from the protocol. Their data
will be included in the intention to treat analysis. If a patient
or their representative withdraws consent for data collection,
we will use only data up to the point of withdrawal in the analysis.

Baseline characteristics
The trial Entry Form (Supplementary File 1) will be used to
collect baseline information including age, sex, time since
injury, systolic blood pressure, Glasgow coma score, pupil
reaction, and if relevant, the location of intracranial haemorrhage. To check that randomisation produced similar groups,
we will describe the baseline characteristics of each group
with frequencies, percentages, means, medians and standard
deviations as appropriate.
Primary outcome
The primary outcome is head injury death in hospital within
28 days of injury among patients randomised within 3 hours
of injury. Because there are strong scientific reasons to expect
that tranexamic acid will be most effective in patients treated
within an hour of injury and less effective with increasing treatment delay, the effect in patients treated within one hour of
injury is of particular interest. Cause of death is assessed and
recorded by the responsible clinician. Although some misclassification is inevitable, all-cause mortality combines causes of death
that might be affected by tranexamic acid (e.g. head injury death)
with causes that we do not expect to be affected by tranexamic
acid (e.g. sepsis death) and this will dilute any effect.
In the original trial protocol, the primary end-point included
all patients randomised within 8 hours of injury. This was
based on the CRASH-2 trial results which showed that giving
tranexamic acid to patients with traumatic extra-cranial bleeding
within eight hours of injury reduces death due to bleeding and
all-cause mortality11. However, pre-specified subgroup analyses
showed that the effect of tranexamic acid depends on the time
interval between the injury and start of treatment12. Treatment
within three hours of injury substantially reduced death due
to bleeding and all-cause mortality whereas treatment started
after three hours appeared to increase death due to bleeding
and had no effect on all-cause mortality. Although we expected
early treatment to be most effective, we did not expect such a
qualitative time to treatment interaction. It is unusual for a
treatment to be beneficial in one subgroup and completely
ineffective or harmful in another.
In response to the CRASH-2 trial results, research was
conducted into the mechanism of action of tranexamic acid in
trauma patients. This research provided a biological explanation
for the time to treatment interaction. Early fibrinolysis is common

after trauma and is associated with increased mortality17–19.
Trauma triggers the early release of tissue plasminogen activator
(TPA), the enzyme that converts plasminogen into the fibrinolytic enzyme plasmin20,21. Plasmin activation leads to fibrinolysis
and profuse bleeding. TPA levels peak about 30 minutes after
injury and plasmin levels peak around one hour21. By inhibiting
early fibrinolysis, tranexamic acid prevents early exsanguination17.
However, the effects are short lived. About two hours
after injury, plasminogen activator inhibitor-1 (PAI-1) levels
start to increase reaching a peak at three hours21. PAI-1 inhibits
fibrinolysis22. This might explain why early tranexamic acid
treatment is so important12. The adverse effects of late tranexamic acid administration could be due to PAI-1-induced
suppression of fibrinolysis and the onset of thrombotic disseminated intravascular coagulation (DIC). By inhibiting
fibrinolysis, tranexamic acid might worsen DIC. Although
the pathology is thrombotic, due to consumption of clotting
factors, thrombotic DIC usually manifests as bleeding. Because
TBI patients show similar coagulation changes, a similar time to
treatment interaction is possible23–25.
In 2016 we obtained results from the WOMAN trial of the effect
of tranexamic acid on death due to bleeding after post-partum
haemorrhage (the results were published in 2017). The WOMAN
trial provided more evidence in support of a time to treatment
interaction. Treatment within three hours significantly reduced
death due to bleeding but there was no evidence of any benefit beyond three hours13. In light of the accumulating evidence
that tranexamic acid treatment is unlikely to be effective when
started more than three hours after injury, in September 2016,
we restricted CRASH-3 trial recruitment to patients within 3 hours
of injury and changed the primary end point accordingly.
In 2017, we published an individual patient-level data metaanalysis of randomised trials of tranexamic acid in acute severe
bleeding. The results showed that immediate treatment improved
survival by more than 70% (OR 1·72, 95% CI 1·42–2·10; p<0·0001)
but thereafter, the survival benefit decreased by about 10% for
every 15 min of treatment delay until 3 hours, after which there
was no benefit14. It is reasonable to expect a similar decline in
treatment benefit in the context of acute intracranial bleeding.
Because the treatment effect in patients treated within 3 hours
of injury will be a weighted average of the effects in the first,
second and third hours after injury, and most patients (about
80%) are recruited in the second and third hours, the overall
effect could be diluted towards the null. For this reason the effect
of treatment in patients treated within an hour of injury is of
particular scientific interest. It is important to bear in mind that if
tranexamic acid is shown to be safe and effective, time to treatment in clinical practice can be much shorter than in a clinical
trial since there is no requirement for consent procedures and the
treatment can be given earlier in the clinical pathway (e.g.
pre-hospital).
In summary, although intracranial bleeding can continue up to
24 hours after injury, research published since the start of the
CRASH-3 trial showed that treatment started beyond 3 hours
of injury is unlikely to be effective and that even within the first
three hours, earlier treatment is more likely to be of benefit. For
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these reasons, we changed the primary outcome to head injury
death in patients randomised within 3 hours of injury with a
focus on the effect in the first hour. All outcomes for patients
treated after three hours of injury will be presented separately.

Primary analysis
The main analyses will compare those allocated tranexamic
acid versus those allocated placebo, on an intention to treat
basis (irrespective of whether they received the allocated treatment). The primary analyses will be presented as relative
risks and 95% confidence intervals. Kaplan-Meier estimates
for the time to each of the primary and secondary outcomes
will also be plotted (with their associated log-rank p-values).
Sensitivity analysis
TBI patients who have a GCS of 3 and bilateral un-reactive pupils
have a very poor prognosis, with a mortality risk of about 75%.
The inclusion in the CRASH-3 trial of such severely injured
patients, who may have little potential to benefit from the trial
treatment, would bias the treatment effect towards the null.
We will therefore conduct a sensitivity analysis on the primary
endpoint that excludes patients with a GCS 3 and bilateral
unreactive pupils.

Missing data
Given the progress of data collection so far, we expect that loss
to follow-up will be minimal (i.e. less than 1% missing data
on the primary outcome) and so we will not impute missing
values.
Sub-group analyses
We will define all subgroups according to variables measured
before randomisation. We will carry out the following subgroup
analyses for head injury deaths.
(a) Time to treatment
We expect that the effect of tranexamic acid on death from head
injury will vary by time to treatment with earlier treatment being
most effective. We will examine this hypothesis by conducting
sub-group analysis of the effect of tranexamic acid according
to the estimated time interval between injury and randomisation
(≤1, >1–≤3, >3h). Because TBI severity (GCS and pupil response),
SBP and age could confound the impact of time to treatment
on treatment effectiveness (Figure 1), we will control for these
variables in a multivariable model. Because there is prior evidence
to expect a time to treatment interaction, we do not require as
strong evidence against the null hypothesis of homogeneity

Figure 1. Relationship between baseline prognostic variables (dilated pupils, GCS, blood pressure and age) and time to treatment in
hours. Based on blinded data on approximately 10,000 patients from the CRASH-3 trial.
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as we might usually require. Most trials lack power to detect
heterogeneity in treatment effects and the lack of a statistically
significant interaction does not mean that the overall treatment effect applies to all TBI patients. Because there is prior
evidence that late treatment may be ineffective or harmful, we
will consider the results of the time to treatment sub-group
analysis in the context of the existing trial data (including data
from the CRASH-2 trial) on the time to treatment interaction
with tranexamic acid and rely more on scientific judgment than
on statistical tests. Because missing data for time to treatment
is minimal, only patients with time to treatment data will be
included in the analyses.
(b) Severity of head injury
We will examine the effect of tranexamic acid on death from
head injury stratified by the severity of TBI at baseline. We
will examine three sub-groups: mild (GCS 13-15), moderate
(GCS 9-12) and severe (GCS 3-8). We will use interaction
tests to see whether the effect of the treatment (if any) differs
across these subgroups. We will also assess the impact of baseline severity on the treatment effect in a regression analysis that
includes continuous terms for severity and its square (because of
potential non-linearity of the treatment effect). Because time to
treatment, SBP and age could confound impact of severity on
treatment effectiveness, we will control for these variables. We
do not expect the effect of tranexamic acid to vary substantially
by severity of TBI and unless there is strong evidence against
the null hypothesis of homogeneity of effects (i.e. p<0.001) the
overall relative risk will be considered the most reliable guide to
the approximate treatment effect in all patients.
(c) Age
There is evidence that fibrinolytic activation following TBI is
greater in older patients26. For this reason, we will examine
the effect of tranexamic acid on head injury death stratified
by age. We will examine three age strata: young (<30 years),
middle (31–60 years), older (>60 years). Because time to treatment, TBI severity and SBP could confound the effect of age
on treatment effectiveness, we will control for these variables.
We will use interaction tests to see whether the effect of the
treatment (if any) differs across these subgroups. We do not
expect the effect of tranexamic acid to vary substantially by age
and unless there is strong evidence against the null hypothesis
of homogeneity of effects (i.e. p<0.001) the overall relative risk
will be considered the most reliable guide to the approximate
treatment effect in all patients.

Secondary outcomes
Early head injury death: Because early head injury deaths are
more likely to be the result of intracranial haemorrhage (since
bleeding occurs early) than late head injury deaths (these are
more likely due to non-bleeding causes that are unaffected by
TXA), we will examine the effect of TXA on head injury deaths
within 48 hours and 7 days of randomisation.
Cause specific mortality: We will assess and report the effect
of tranexamic acid on all-cause mortality and cause specific
mortality using relative risks and 95% confidence intervals.

We will also present the distribution of causes of death by days
since randomisation.
Disability: We assess disability using the Disability Rating Scale
and with a set of disability questions based on discussions with
victim representatives. The Disability Rating Scale measures the
level of disability in six diagnostic categories: (1) eye opening,
(2) best verbal response, (3) best motor response, (4) self-care
ability for feeding, grooming and toileting, (5) level of cognitive
functioning, and (6) employability. We can use the Disability
Rating Scale across the span of recovery. The maximum score a
patient can obtain is 29, which represents an extreme vegetative state. A person without disability would score zero. We will
assess the effect of tranexamic acid on disability by comparing
the mean Disability Rating Scale score in the tranexamic acid
and placebo groups using parametric and non-parametric tests.
We will report the effect of tranexamic acid on the patient
derived disability measure by estimating the risk ratio of being
in the extreme categories for each of the six areas of functioning (1. walking, 2. washing, 3. pain and discomfort, 4. anxiety or
depression, 5. agitation or aggression and 6. fatigue).
Vascular occlusive events: By inhibiting fibrinolysis, tranexamic
acid could increase the risk of cerebral ischaemia and thrombosis. Cerebral ischaemia is a common pathophysiological
mechanism after TBI that can worsen neurological outcome
and increase mortality. Raised intracranial pressure could lead
to cerebral hypo-perfusion and thrombotic DIC might increase
the risk of the cerebral micro-thrombi. These thrombi are
often found in autopsies of patients with severe TBI. We will
assess and report the effect of tranexamic acid on the risk ratio
for fatal and non-fatal stroke both overall and stratified by
time to treatment (less than versus more than 3 hours). The
effect of tranexamic acid on cerebral infarction will be further
evaluated using routine brain imaging from a selection of trial
patients (sub-study to be published separately). The effect of
tranexamic acid on other vascular occlusive events (fatal and
non-fatal myocardial infarction, deep vein thrombosis and pulmonary embolism) will be reported both separately and combined.
Seizures: Tranexamic acid crosses the blood-brain barrier and
in high dosages causes seizures. Although there was no increase
in seizures in the CRASH-2 trial of tranexamic acid in extracranial bleeding, seizure activity is more common after TBI
and remains a concern. We will therefore report the effect of
tranexamic acid on the risk ratio for seizures.
Neurosurgical interventions for intracranial haemorrhage: If
tranexamic acid treatment reduces intracranial bleeding it might
reduce neurosurgical intervention for bleeding. On the other
hand, if neurosurgical intervention precedes or coincides with
administration of the trial treatment, there will be no opportunity
for tranexamic acid to have an effect. We expect that including
such patients in the analysis will dilute the treatment effect
towards the null. Although tranexamic acid might not have
enough time to reduce the need for neurosurgical intervention in
the first place, it should have enough time to reduce the amount
of bleeding during the operation. We will report the effect of
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tranexamic acid on haematoma evacuation and the mean blood
loss in tranexamic acid and placebo treated patients. We will
test the effect of treatment allocation on haematoma evacuation
using relative risks and 95% confidence intervals. We will test
the effect of treatment allocation on mean blood loss using a
two-sample t-test.
Complications: Patients with TBI are at risk of other significant
medical events including renal failure, sepsis and gastrointestinal
bleeding and these outcomes are collected routinely.
Adverse events: We collect other untoward medical events up
to 42 days after randomisation as adverse events (AEs). In line
with ICH-GCP guidelines, an AE is considered as serious if
it results in death, is life-threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in
persistent or significant disability/incapacity, or in a congenital
anomaly/birth defect16. If there is a possibility that an AE is due
to the trial drug, it is an adverse reaction. A suspected unexpected serious adverse reaction (SUSAR) is an unexpected
occurrence of a serious adverse reaction. There need only be an
index of suspicion that the event is a previously unreported reaction to a trial drug or a previously reported but exaggerated or
unexpectedly frequent adverse drug reaction.
The number of AEs, SAEs, SUSARs grouped by MedDRA®
codes and the number of patients with at least one event will be
compared between arms using a chi-squared test (or Fisher’s
exact test), with relative risks and 95% confidence intervals when
these are computable.

Other analyses: to be reported in separate
publications
Analysis 1. Reducing the impact of null bias
We will examine the timing of the effect of tranexamic acid on
outcomes among patients treated within three hours of injury, by
conducting repeated analyses excluding outcomes at increasing
time intervals from randomisation. We will increase the length
of the exclusion period by one hour at a time. This means that
patients who die quickly following randomisation (who are
more likely to have un-survivable injuries at baseline) can
be excluded and the treatment effect evaluated without this
null bias. Risk ratios and 95% confidence intervals will be
estimated to assess the size and precision of the treatment effect.

Analysis 2: Adjusting for possible imbalance in baseline
prognostic factors
Given the size of the CRASH-3 trial, baseline characteristics
that may influence the outcome should be evenly distributed
between the treatment and placebo groups, so that any difference
in outcome can be attributed to the intervention. However, it
is still possible that a chance imbalance in important prognostic factors could influence the results. To investigate this
possibility, we will conduct an analysis of the effect of treatment that is adjusted for baseline risk. We will build a prognostic
model based on pre-specified baseline variables and use it
to estimate the predicted risk of the outcome at baseline.

The primary outcome is head injury death. The most important
prognostic factors for this outcome that are measured at baseline are age, GCS score, pupil reactivity and systolic blood
pressure. These variables will be included in a multivariable
prognostic model based on the final trial dataset. Although there
are almost complete data on these variables, in the case of missing data, the missing values. The trial data will then be stratified
into risk deciles as shown in the Table based on the predicted
risk of the outcomes at baseline. We will report frequencies and
percentages within each risk decile, and calculate a risk ratio
(with 95% CI) for each risk decile. The pooled risk ratio (with
a 95% CI) will be estimated as an inverse variance weighted
average of the stratum specific risk ratios. The pooled risk
ratio should provide an estimate of the treatment effect that is
un-confounded by baseline risk. The advantage of this approach
is that the effect of baseline risk on the treatment effect is more
explicit than when covariate adjusted odds ratios are calculated
using logistic regression. Furthermore, risk ratios are easier
to interpret and apply to individual patients than are odds ratios.
A forest plot will be prepared to show graphically how the
treatment effect varies by baseline risk. We will use a chi-squared
test to assess any heterogeneity in treatment effect across the
risk groups and we will calculate the I-squared statistic to quantify the percentage of variability in effect estimates that is due
to heterogeneity rather than chance. To reduce the likelihood
of making inappropriate inferences, we pre-specify that unless
there is strong evidence against the null hypothesis of homogeneity of effects (i.e. P<0.001), the pooled relative risk will be
considered the most reliable guide to the approximate treatment
effects in all risk strata. We do not anticipate substantial heterogeneity by baseline risk.

Analysis 3: Cost effectiveness
An economic analysis will be relevant if tranexamic acid clearly
demonstrates efficacy in achieving its clinical aims. In this case,
the study will be undertaken in the form of a cost-effectiveness
analysis with the aim of estimating the incremental costeffectiveness ratio comparing the use of tranexamic acid with
normal clinical practice. Analysis will be based on adjusted
life years gained. A further analysis will explore the use of
the EQ-5D data to quality-adjusted survival. In this study, the
economic analysis is clearly bounded as virtually all significant
resource use will occur in the initial period of hospitalisation. As
such, neither a long-term resource analysis nor an analysis
of out of hospital costs will be required. The trial use of tranexamic acid is likely to mirror its use in normal clinical practice,
hence the cost-effectiveness estimated in the trial (adjusted for
protocol driven costs) will closely approximate cost-effectiveness
in actual clinical practice. Data on physical resource consumption (e.g. length and nature of hospital stay) will be collected
for each patient and a common unit cost at a country level will
be applied. A sensitivity analysis will be undertaken to assess
the robustness of the economic analysis in response to variations in key variables such as drug prices. In all cases, the
economic analysis will be integrated with the clinical trial
procedures to optimise efficiency and minimise inconvenience
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to patients. Time in the Intensive Care Unit (ICU) is the key
resource consumption variable. Length of stay in the ICU and the
hospital will be censored due to early deaths, or a stay in the ICU
or hospital longer than 42 days. Summary statistics will include
the median and the interquartile range computed separately
for each treatment arm.

Analysis 4: Examining the mechanism of action of
tranexamic acid in TBI
An Intracranial Bleeding Mechanistic Sub-Study (IBMS) is nested
in a cohort of approximately 1,000 CRASH-3 trial patients. This
sub-study aims to examine the mechanism of action of tranexamic acid by evaluating brain images acquired before and
after randomisation16. Brain images are primarily examined for
evidence of intracranial haemorrhage and cerebral infarction.
Patients who have a GCS score of 12 or less or intracranial bleeding on a CT scan done before randomisation are eligible for
inclusion. The results of the IBMS will be published when the
CRASH-3 trial is complete. The IBMS protocol has been
published and the associated statistical analysis plan will be
published prior to completion of the CRASH-3 trial.
Data monitoring and interim analyses
An independent Data Monitoring Committee is responsible
for reviewing the progress of the CRASH-3 trial, including
recruitment, data quality, and main outcomes and safety data.
The DMC has the responsibility for deciding whether, while
randomisation is in progress, the unblinded results (or the
unblinded results for a particular subgroup), should be revealed
to the Trial Steering Committee. They will do this if, and only if,
two conditions are satisfied: (1) The results provide proof beyond
reasonable doubt that treatment is on balance either definitely
harmful or definitely favourable for all, or for a particular category of, participants in terms of the major outcome; and (2) The
results, if revealed, would be expected to substantially change the
prescribing patterns of clinicians who are already familiar with
other trial results that exist. Exact criteria for “proof beyond
reasonable doubt” are not, and cannot be, specified by a purely
mathematical stopping rule, but they are strongly influenced
by such rules. This is in agreement with the Peto-Haybittle
stopping rule27 whereby an interim analysis of major endpoint
would generally need to involve a difference between treatment
and control of at least three standard errors to justify premature
disclosure. An interim subgroup analysis would have to be even
more extreme to justify disclosure. This rule has the advantage that the exact number and timing of interim analyses need
not be pre-specified. In summary, the stopping rules require
extreme differences to justify premature disclosure and involve
an appropriate combination of mathematical stopping rules and
scientific judgment. To date, five interim analyses have been
conducted by the Data Monitoring Committee with no recommendation for early stopping. These analyses were conducted
in June 2012, March 2014, July 2015, May 2016 and December
2017, and involved the complete analysis of the un-blinded data
as per the trial protocol. There was no change to the protocol as
a result of the interim analyses and there are no more interim
analyses planned. There are no interim analyses planned for
the IBMS. The final analysis of the unblinded results will take
place after recruitment is complete and the database is hardlocked.

Data management and analysis software
All trial data is managed in accord with the CRASH-3 trial
Data Management Plan (DMP) (version 1.1) and stored in the
Trial Master File. The DMP standard operating procedures are
produced in conjunction with the London School of Hygiene
and Tropical Medicine (LSHTM) policies and procedures,
the Clinical Trials Unit working procedures, and regulatory
requirements. The clinical database management system for
CRASH-3 trial and IBMS was built to comply with ICH-GCP.
The database was developed by Sealed Envelope Ltd (UK).
In the CRASH-3 trial, data are collected at each participating site and transmitted directly to the Clinical Trials Unit via
the database. Where there is poor internet connection, the paper
CRFs can be sent by fax or via email. Data checks and cleaning
are performed by the Clinical Trials Unit. Data items to be
coded including Adverse Event term and terms used to describe
‘other’ causes of death on the Outcome Form are coded
using MedDRA Version 12. In the IBMS, the outcome data is
directly uploaded onto an electronic database accessed at each
sub-study site. The final database lock will take place at the
end of the trial within three months from the time when the
‘Last patient’ in the ‘Last follow-up’ has completed the trial.
Data will be exported for statistical analysis using the most
recent version of Stata [StataCorp LP, College Station, Texas,
USA].
Dissemination of findings
The results of the CRASH-3 trial will be published in an established peer-reviewed journal. At least one publication of the
main trial results will be made. Links to the publication will
be provided in all applicable trial registers. Dissemination of
results to patients will take place via the media, trial website and
relevant patient organizations. In addition, participants and their
families will be made aware of the trial results if requested.
Collaborating investigators will play a vital role in disseminating the results to colleagues and patients. The success of the trial
will be dependent entirely upon the collaboration of the nurses
and doctors in the participating hospitals and those who hold key
responsibility for the trial. Hence, the credit for the study will
be assigned to the key collaborator(s) from each participating
site, as it is crucial that those taking credit for the work have
actually carried it out. The results of the trial will be reported
first to trial collaborators. As a large number of hospitals in many
countries will contribute to this trial, individual countries or
sites cannot restrict the publication of the manuscript relating to the outcomes of this trial. Anonymous data for this trial
will be made available for free use at The Free Bank of Injury
and emergency Research Data (freeBIRD) website. Following
publication of the primary and secondary analyses detailed in
this statistical analysis plan, the trial data will be made available via our data sharing portal - The Free Bank of Injury and
emergency Research Data (freeBIRD) website. This will allow for
maximum utilization of the data to improve patient care and
advance medical knowledge.
Study status
The trial is currently recruiting patients and at the time of
writing a total of 11,500 patients had been enrolled (target sample
size 13,000).
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Discussion
This statistical analysis plan is an update to our previously
published protocols. The main changes are: an increased
sample size from 10,000 to 13,000 patients, and a change in the
primary end point to death in hospital within 28 days of injury
among patients randomised within 3 hours of injury but with a
focus on very early treatment. We present our plan for the statistical analyses in advance of the database lock and un-blinding to
guard against data dependent analyses. The CRASH-3 trial should
provide reliable evidence on the effect of tranexamic acid on
death and disability in patients with TBI.

Data availability

programme for the United Kingdom [14/190/01]. Funding for
recruitment in the European Union and North America is provided by the London School of Hygiene and Tropical Medicine
[EPNPBH61]. The IBMS is fully funded by the London School of
Hygiene and Tropical Medicine [EPAA6020]. The design, management and interpretation of the CRASH-3 trial and IBMS are
entirely independent of the manufacturers of tranexamic acid or
the funders. Proof of all funding has been provided and reviewed
on publication of the CRASH-3 trial and IBMS protocols15,16.
The JP Moulton Charitable Trust (United Kingdom)
is funding the run-in costs for the CRASH-3 trial and the
recruitment of up to 500 patients.

No data are associated with this article.
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Comments: (page numbers refer to the pdf version)
Abstract
One of the major reasons for the change is the focus on patients receiving treatment within 3 hours of
injury and the sample size was modified to accommodate this. It is unclear from the abstract though what
the (new) target enrolment number is for those patients that receive treatment within 3 hours. This also
does not seem to be clear from the text. There should either be a mentioning of the revised target sample
size for those who receive treatment within three hours or a justification why that is not given.
It would be helpful to state in the abstract the timeframe for the mortality outcomes for the secondary
outcomes (are they the same as for the primary?).
It is unclear (but might difficult to explain concisely) what is meant by subgroup .. stratified by “baseline
risk”. How is baseline risk defined?
Generally
In the emergency setting it is difficult to imagine that the time from injury to treatment can be measured
exactly. It would be helpful to discuss this at least to some degree and to consider adding the word
“estimated” if that is judged to be appropriate.
Another subject that would be good to provide a little further information (unless it is in one of the
referenced docs) is how “discharged alive” is defined. E.g. what about discharge to hospice?

“list of abbreviations section” SUSARs: Suspected unexpected rather than Suspected unsuspected.
Regarding page 3 left column at the bottom: would be good to mention “blinded” here as well.
Regarding section Randomisation and masking: might be helpful to mention the TXA dose here as well.
Regarding section “sample size”, I don’t understand why the updated sample size calculations can not be
provided. If there is a reason for why, the reason should be given/described.
Regarding section “Baseline characteristics” At the end of the paragraph it is indicated that baseline
characteristics of each group will be described with frequencies and percentages. Is that sufficient? How
about for continuous variables? Or are they all dichotomized or divided into categories?
Regarding page 5 left column second paragraph, “however…” it seems that if this is the primary
justification, the article was published in 2011, why wait until 2016 to make the change? Just an additional
comment regarding the reason for the time lapse would be good.
Regarding Primary analysis: If I am not mistaken, two measures (relative and absolute risks) are
suggested for the primary analysis. This can lead to multiple comparison issues and what would be done
if the results were contradictory? It would be best to choose one specific analysis for the primary analysis
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suggested for the primary analysis. This can lead to multiple comparison issues and what would be done
if the results were contradictory? It would be best to choose one specific analysis for the primary analysis
and suggest the other one as secondary.
Regarding Missing data: Is there any evidence/data to suggest that patients (or family members) might
withdraw consent?
Regarding Figure 1: Did I miss it, or what were the data the graphs are based on? Where do these data
for the graphs come from?
Regarding secondary outcomes: … “will examine the effect of TXA on head injury deaths within 48 hours
and 7 days of randomisation”. This could be problematic, if TXA were to contribute to more deaths within
the first 48 hours.
Regarding section “disability”: at what time point(s) are those disability measures taken. Why are both
parametric and non-parametric tests proposed? What would be the conclusions if the test disagree? How
would adjustments be made for multiple comparisons if any?
Regarding section: “Neurosurgical intervention for intracranial haemorrhage” why aren’t specific statistical
test proposed in other sections except here (t-test)?
Regarding “Other analysis: to be reported in separate publications” Excluding early deaths is said to allow
evaluation of treatment effect “without this null bias”. But if TXA has some effect on early patient survival,
the result might be that patients on TXA are sicker if early deaths are excluded.
Regarding p8 left column paragraph starting with “the primary outcome…”: “missing values will be
replaced by the mean of the observed data” such single imputation approach will lead to underestimating
the variability in the data and depending on the actual amount of missingness (even though the authors
assume it is going to be a small amount) can lead to serious bias in estimating the variability in the data
and should be avoided.
Regarding p8 right column: “However, we hypothesise that the risk reduction with tranexamic acid would
be greatest in patients at low risk of death since a smaller proportion of these patients will have
un-survivable TBI”. This depends on how “low risk” is defined, as in this population one might expect a
certain percentage of patients who get better without even needing TXA (thus at low risk, e.g. patients
who are intoxicated and have a TBI, it is very difficult to tell at the time of treatment initiation how severely
they are actually injured and whether or not they would need any TXA).
Regarding Analysis 3: censoring deaths for length of ICU stay: similar to excluding early deaths,
censoring of deaths for this analysis could seriously bias the results as “censoring” in the analysis typically
carries the assumption of “independent censoring” which is unlikely to be true. Also, if TXA were to have
any beneficial impact on early survival this might result in a longer ICU stay on average for this group and
would be problematic in this analysis.
Regarding line 4 left column p9: write out abbreviation TSC and line -13 write out abbreviation PHP.
Is the rationale for developing the new method (or application) clearly explained?
Yes
Is the description of the method technically sound?
Yes
Are sufficient details provided to allow replication of the method development and its use by
others?
Partly
If any results are presented, are all the source data underlying the results available to ensure full
reproducibility?
No source data required
Are the conclusions about the method and its performance adequately supported by the
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Are the conclusions about the method and its performance adequately supported by the
findings presented in the article?
Yes
Competing Interests: I am the Principal Investigator of another trial examining the effect of TXA in TBI.
This might (or might not) be considered a competing interest by readers.
Referee Expertise: Biostatistics
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
Referee Report 20 August 2018
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Early administration of TXA ( tranexamic acid) within 3 hrs safely reduced the risk of death in bleeding
trauma patients and was found to be highly cost-effective in CRASH 2 study of 20211 patients [ which
included polytrauma subjects with traumatic brain injury also]1. CRASH-3 study aims to evaluate the
effectiveness and safety of TXA in the treatments of isolated brain injury patients. It is believed that early
administration of tranexamic acid in TBI patients might limit intracranial bleeding, reducing death and
disability.
Present study [CRASH-3] now plans to recruit 13000 TBI patients [ Sample size increased by 3000 to get
enough patients within 3 hours of injury instead of earlier proposed 8 hrs ] for randomisation to tranexamic
acid or matching placebo in addition to usual care. The primary outcome is head injury death in hospital
within 28 days of injury for patients treated within 3 hours of injury. Recruitment is unlikely to be an issue
[due to recent protocol update to include patients within 3 hours of injury] as 11500 patients have already
been included in the study [hoping that all/majority of them were randomised and treated within 3 hours of
injury]. Null hypothesis of homogeneity is not required in this study due to available evidence from
CRASH 2 study on the same drug.
Worldwide, about 50 million people have a TBI each year, and it is estimated that about half the world’s
population will have one or more TBIs over their lifetime. Approximately 50% of trauma deaths are likely
related to TBI which would imply that about one TBI-related death occurs every 3 minutes in some nations
(India). Many epidemiological studies based on comparative effectiveness research model (CER) are
currently underway/completed recruitments to better characterize TBI and to identify effective clinical
interventions for TBI care. Centre TBI for adults and ADAPT for children have completed recruitments of
over 5000 ( Adults) and 1000 ( children) already and their results are likely to throw further light on our
understanding of traumatic brain injuries2.
In- hospital 28 days mortality end point analysis as study drug effect may not translate to long term
outcome in TBI subjects for various reasons.We documented influence of achieving early ICU adherence
to head trauma guidelines with significantly lower in-hospital mortality in comparative study of two
centres. Although long-term outcomes generally improved, patients discharged with favourable GOS
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centres. Although long-term outcomes generally improved, patients discharged with favourable GOS
score often deteriorated at home thereby implying influence of need of rehabilitation care for TBI subjects
[ CHIRAG Study]3.
TBI population is quite heterogenous both in terms of mechanism of injury and in prehospital /in-hospital
treatment delays. It may be noted that in some of developing nations prehospital services are still lacking
for most of TBI subjects. Loss of follow up data margin of 1% sounds a bit too optimistic as some of TBI
subjects who live in far off catchments areas may not be available for follow ups after initial discharge from
hospital.
Current statistical analysis plan with increased patient number within three hours of injury and primary
end point of death in hospital within 28 days of injury amongst randomized looks fine and is likely to
provide evidence on effect of this drug on death and disability in patients with TBI. However, for
developing nations where prehospital infrastructure is still lacking, it will be worthwhile looking at results of
this drug or patients treated within 3-8 hours of injury too.
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This manuscript outlines the detail of the revised statistical analysis plan for CRASH-3 trial. The trial is
being conducted to assess the impact of administration of tranexamic acid on the survival of patients with
traumatic brain injury. The study design has been adjusted to improve the likelihood of identifying the
benefit if it exists. This adjustment includes enrolling within a narrower window after head injury. This
adjustment is justified by studies that proved the most benefit from TXA within the first 3 hours of brain
injury. The investigators had to adjust (increase) the sample size to maintain the study power at the
pre-designed level.
The details of the trial objectives, trial outcomes, and the methodology as well as the statistical analysis
plan are well described.
Minor:
- Page 5, under the section Primary Outcome, the authors state: "......The results showed that immediate
treatment improved survival by more than 70% (OR 1.72, 95% CI 1.42-2.10)" The number 70% is
obviously the relative risk reduction. It would be more helpful for the readers to know the absolute risk
reduction/difference. I was not able to calculate the absolute risk difference from the referenced original
trial either.
- Small trails published on this topic have measured the effect of TXA on the size of hematoma as well (in
those with documented brain hematoma). This is clearly not a patient-centered outcome. However, it
would have been interesting for the readers to know why the investigators do not wish to measure this
outcome.
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timing of injury and administration.
Although all-cause mortality is important and robust, disability-free survival (from the DRS) should if
possible also be estimated.
There are some data suggesting that TxA may reduce infection risk, and so both mortality and other
outcomes have pick this up (as opposed to it being "diluted").
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